Oramed Pharm (ORMP) Ratios

531 Followers

Oramed Pharm Ratios

ORMP's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, ORMP's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.

Ratios	TTM	Dec 25	Dec 24	Sep 23	Dec 22
Liquidity Ratios
Current Ratio	―	6.98	25.19	3.06	27.34
Quick Ratio	―	6.98	25.19	3.06	27.34
Cash Ratio	―	2.41	9.57	0.17	7.04
Solvency Ratio	―	2.06	-1.90	0.10	-3.26
Operating Cash Flow Ratio	―	-0.48	-1.48	-0.19	-4.99
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	-0.20	-116.20
Net Current Asset Value	$ ―	$ 102.15M	$ 133.29M	$ 104.93M	$ 146.62M
Leverage Ratios
Debt-to-Assets Ratio	―	<0.01	<0.01	0.23	<0.01
Debt-to-Equity Ratio	―	<0.01	<0.01	0.32	<0.01
Debt-to-Capital Ratio	―	<0.01	<0.01	0.24	<0.01
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	0.00	<0.01
Financial Leverage Ratio	―	1.16	1.06	1.35	1.06
Debt Service Coverage Ratio	―	0.00	-21.17	0.13	-150.11
Interest Coverage Ratio	―	0.00	-14.98	-4.40	0.00
Debt to Market Cap	―	0.00	0.00	0.55	<0.01
Interest Debt Per Share	―	0.02	0.03	1.37	0.02
Net Debt to EBITDA	―	-0.60	3.63	5.81	1.07
Profitability Margins
Gross Profit Margin	―	0.65%	0.00%	100.00%	100.00%
EBIT Margin	―	3766.20%	0.00%	531.72%	-1501.96%
EBITDA Margin	―	3772.25%	0.00%	546.34%	-1367.96%
Operating Profit Margin	―	-754.40%	0.00%	-1176.79%	-1501.96%
Pretax Profit Margin	―	3766.20%	0.00%	379.70%	-1393.41%
Net Profit Margin	―	3202.50%	0.00%	412.31%	-1397.11%
Continuous Operations Profit Margin	―	3200.80%	0.00%	379.70%	-1397.11%
Net Income Per EBT	―	85.03%	119.99%	108.59%	100.27%
EBT Per EBIT	―	-499.23%	124.56%	-32.27%	92.77%
Return on Assets (ROA)	―	27.74%	-12.30%	2.51%	-23.36%
Return on Equity (ROE)	―	32.07%	-13.06%	3.37%	-24.88%
Return on Capital Employed (ROCE)	―	-7.12%	-8.54%	-9.42%	-26.04%
Return on Invested Capital (ROIC)	―	-6.05%	-8.53%	-7.21%	-26.00%
Return on Tangible Assets	―	27.74%	-12.30%	2.51%	-23.36%
Earnings Yield	―	54.28%	-19.33%	5.93%	-8.05%
Efficiency Ratios
Receivables Turnover	―	0.43	0.00	0.00	0.00
Payables Turnover	―	4.49	0.24	0.00	0.00
Inventory Turnover	―	0.00	0.00	0.00	0.00
Fixed Asset Turnover	―	1.50	0.00	0.86	1.49
Asset Turnover	―	<0.01	0.00	<0.01	0.02
Working Capital Turnover Ratio	―	0.02	0.00	0.01	0.02
Cash Conversion Cycle	―	764.69	-1.49K	0.00	0.00
Days of Sales Outstanding	―	846.07	0.00	0.00	0.00
Days of Inventory Outstanding	―	0.00	0.00	0.00	0.00
Days of Payables Outstanding	―	81.38	1.49K	0.00	0.00
Operating Cycle	―	846.07	0.00	0.00	0.00
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.22	-0.21	-0.26	-0.74
Free Cash Flow Per Share	―	-0.27	-0.21	-0.26	-0.75
CapEx Per Share	―	0.05	<0.01	<0.01	0.01
Free Cash Flow to Operating Cash Flow	―	1.21	1.00	1.02	1.02
Dividend Paid and CapEx Coverage Ratio	―	-4.73	-467.36	-40.53	-57.87
Capital Expenditure Coverage Ratio	―	-4.73	-467.36	-40.53	-57.87
Operating Cash Flow Coverage Ratio	―	-11.08	-22.61	-0.20	-32.10
Operating Cash Flow to Sales Ratio	―	-4.57	0.00	-7.68	-10.62
Free Cash Flow Yield	―	-9.39%	-8.53%	-11.33%	-6.22%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	1.84	-5.17	16.86	-12.42
Price-to-Sales (P/S) Ratio	―	59.00	0.00	69.50	173.56
Price-to-Book (P/B) Ratio	―	0.59	0.68	0.57	3.09
Price-to-Free Cash Flow (P/FCF) Ratio	―	-10.65	-11.72	-8.83	-16.07
Price-to-Operating Cash Flow Ratio	―	-12.90	-11.75	-9.05	-16.35
Price-to-Earnings Growth (PEG) Ratio	―	>-0.01	0.01	-0.15	-0.51
Price-to-Fair Value	―	0.59	0.68	0.57	3.09
Enterprise Value Multiple	―	0.97	-3.01	18.54	-11.62
Enterprise Value	―	72.88M	44.76M	135.69M	429.57M
EV to EBITDA	―	0.97	-3.01	18.54	-11.62
EV to Sales	―	36.44	0.00	101.26	158.92
EV to Free Cash Flow	―	-6.58	-5.31	-12.86	-14.71
EV to Operating Cash Flow	―	-7.97	-5.32	-13.18	-14.97
Tangible Book Value Per Share	―	4.82	3.56	4.04	3.88
Shareholders’ Equity Per Share	―	4.82	3.58	4.06	3.89
Tax and Other Ratios
Effective Tax Rate	―	0.15	-0.20	0.00	>-0.01
Revenue Per Share	―	0.05	0.00	0.03	0.07
Net Income Per Share	―	1.55	-0.47	0.14	-0.97
Tax Burden	―	0.85	1.20	1.09	1.00
Interest Burden	―	1.00	1.06	0.71	0.93
Research & Development to Revenue	―	3.19	0.00	6.69	10.23
SG&A to Revenue	―	4.36	0.00	6.29	5.11
Stock-Based Compensation to Revenue	―	3.00	0.00	0.00	0.00
Income Quality	―	-0.14	0.44	-1.86	0.79

Currency in USD